CSIMarket
 


Cara Therapeutics inc   (CARA)
Other Ticker:  
 
 

CARA's Revenue Growth by Quarter and Year

Cara Therapeutics Inc 's Revenue results by quarter and year




CARA Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 3.00 3.26 20.27 9.27
III Quarter September 4.87 10.81 0.00 5.63
II Quarter June 6.93 23.00 1.94 8.09
I Quarter March 6.17 4.79 112.09 4.51
FY   20.97 41.86 134.30 27.50



CARA Revenue fourth quarter 2023 Y/Y Growth Comment
Cara Therapeutics Inc reported decrease in Revenue in the fourth quarter 2023 by -7.85% to $ 3.00 millions, from the same quarter in 2022.
The decrease in the fourth quarter 2023 Cara Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 38319.2%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 89 other companies have achieved higher Revenue growth. While Cara Therapeutics Inc ' s Revenue decline of -7.85% ranks overall at the positon no. 1874 in the fourth quarter 2023.




CARA Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -7.85 % -83.92 % 118.66 % 60.1 %
III Quarter September -54.95 % - - 8.06 %
II Quarter June -69.87 % 1085.57 % -76.02 % 84.7 %
I Quarter March 28.81 % -95.73 % 2385.37 % -18.44 %
FY   -49.89 % -68.83 % 388.36 % 31.52 %

Financial Statements
Cara Therapeutics Inc 's fourth quarter 2023 Revenue $ 3.00 millions CARA's Income Statement
Cara Therapeutics Inc 's fourth quarter 2022 Revenue $ 3.26 millions Quarterly CARA's Income Statement
New: More CARA's historic Revenue Growth >>


CARA Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -38.32 % -69.84 % - 64.65 %
III Quarter September -29.73 % -53 % - -30.41 %
II Quarter June 12.32 % 380.17 % -98.27 % 79.38 %
I Quarter March 89.26 % -76.37 % 1109.17 % -22.11 %
FY (Year on Year)   -49.89 % -68.83 % 388.36 % 31.52 %




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #90
Healthcare Sector #255
Overall #1874

Revenue Y/Y Growth Statistics
High Average Low
868432.92 % 38319.2 % -100 %
(Apr 01 2016)   (Jun 30 2021)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #90
Healthcare Sector #255
Overall #1874
Revenue Y/Y Growth Statistics
High Average Low
868432.92 % 38319.2 % -100 %
(Apr 01 2016)   (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Cara Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1598634.18 % 50102.95 % -100 %
(Sep 30 2016)  


CARA's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Cara Therapeutics Inc reported fall in Revenue from the previous quarter by -38.32% to $ 3.00 millions, from $ 4.87 millions achived in the previous quarter.

This is not big problem, as Cara Therapeutics Inc 's Revenue generally tend to dip in the IV. Quarter.

Within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Revenue quarter on quarter growth. While Cara Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 1955.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #85
Healthcare Sector #236
Overall #1955
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #85
Healthcare Sector #236
Overall #1955
Revenue Q/Q Growth Statistics
High Average Low
1598634.18 % 50102.95 % -100 %
(Sep 30 2016)  


CARA's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2023 Cara Therapeutics Inc disclosed fall in Revenue from the previous quarter by -38.32% to $ 3.00 millions, from $ 4.87 millions achived in the previous quarter.

As we evaluate recent shortcoming in the IV. Quarter 2023, we should take into consideration, that frequently IV. Quarter Revenue emerge weaker relative to the preciding period

Within Major Pharmaceutical Preparations industry 84 other companies have achieved higher Revenue quarter on quarter growth. While Cara Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 1955.


Cara Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 20.97 $ 21.23 $ 27.17 $ 43.24 $ 41.87
Y / Y Revenue Growth (TTM) -49.92 % -63.95 % - - -
Year on Year Revenue Growth Overall Ranking # 1980 # 3557 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) -1.21 % -21.89 % -37.16 % 3.28 % -28.89 %
Seq. Revenue Growth (TTM) Overall Ranking # 1888 # 2860 # 1777 # 3676 # 2004




Cumulative Revenue growth Comment
Cara Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2023. If the fiscal year would end in Dec 31 2023, Cara Therapeutics Inc 's annual Revenue drop would be -49.92% year on year to $21 millions.

In the Healthcare sector 234 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1980, from total ranking in previous quarter at 3557.

Revenue TTM Q/Q Growth Statistics
High Average Low
177764.98 %
16128.06 %
-100 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 80
Healthcare Sector # 235
Overall # 1980

Revenue TTM Y/Y Growth Statistics
High Average Low
177764.98 %
16128.06 %
-100 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 80
Sector # 224
S&P 500 # 1888
Cumulative Revenue growth Comment
Cara Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Sep 30 2023. If the fiscal year would end in Dec 31 2023, Cara Therapeutics Inc 's annual Revenue drop would be -49.92% year on year to $21 millions.

In the Healthcare sector 234 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1980, from total ranking in previous quarter at 3557.

Revenue TTM Q/Q Growth Statistics
High Average Low
177764.98 %
16128.06 %
-100 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 80
Healthcare Sector # 235
Overall # 1980

Revenue TTM Y/Y Growth Statistics
High Average Low
177764.98 %
16128.06 %
-100 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 80
Sector # 224
S&P 500 # 1888




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CARA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for CARA's Competitors
Revenue Growth for Cara Therapeutics Inc 's Suppliers
Revenue Growth for CARA's Customers

You may also want to know
CARA's Annual Growth Rates CARA's Profitability Ratios CARA's Asset Turnover Ratio CARA's Dividend Growth
CARA's Roe CARA's Valuation Ratios CARA's Financial Strength Ratios CARA's Dividend Payout Ratio
CARA's Roa CARA's Inventory Turnover Ratio CARA's Growth Rates CARA's Dividend Comparisons



Companies with similar Revenue drop for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Healthcare Services Group Inc -0.04%$ -0.042 millions
Integra Lifesciences Holdings Corp-0.25%$ -0.247 millions
National Research Corporation-0.37%$ -0.375 millions
The Beauty Health Company-0.63%$ -0.633 millions
3m Company-0.82%$ -0.817 millions
Viatris Inc -1.00%$ -0.998 millions
Quest Diagnostics Inc-1.93%$ -1.929 millions
Koru Medical Systems Inc-2.16%$ -2.161 millions
Envista Holdings Corporation-2.30%$ -2.300 millions
Zynex inc -3.11%$ -3.114 millions
Baxter International Inc -3.55%$ -3.550 millions
Caribou Biosciences Inc -3.63%$ -3.629 millions
Gilead Sciences Inc -3.72%$ -3.722 millions
Lifevantage Corp-3.92%$ -3.921 millions
Avantor Inc -4.02%$ -4.022 millions
Escalon Medical Corp -4.53%$ -4.533 millions
Inovio Pharmaceuticals Inc -4.55%$ -4.553 millions
Optinose Inc -4.76%$ -4.756 millions
Cryoport inc -5.13%$ -5.133 millions
Hookipa Pharma inc -5.38%$ -5.378 millions
Abbvie inc -5.42%$ -5.423 millions
Hologic Inc-5.69%$ -5.688 millions
Encision Inc -6.08%$ -6.083 millions
Biogen Inc -6.20%$ -6.199 millions
Curis Inc -6.62%$ -6.616 millions
Bio rad Laboratories Inc -6.62%$ -6.621 millions
Charles River Laboratories International inc -7.85%$ -7.853 millions
Cara Therapeutics inc -7.88%$ -7.881 millions
Arcus Biosciences Inc -7.89%$ -7.889 millions
Qiagen N v -8.67%$ -8.666 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com